Therapeutic Classification: antiparkinson agents
Pharmacologic Classification: monoamine oxidase type b inhibitors
Absorption: 36% absorbed following oral administration.
Distribution: Extensively distributed to tissues; readily crosses the blood-brain barrier.
Half-Life: 1.3 hr; does not correlate with duration of MAO-B inhibition.
Contraindicated in:
Use Cautiously in:
CV: orthostatic hypotension (may ↑ levodopa-induced hypotension), ↑BP, chest pain, syncope
Derm: ↑melanoma risk, alopecia, ecchymosis, rash
EENT: conjunctivitis, rhinitis
GI: ↓weight, anorexia, dizziness, dyspepsia, gastroenteritis, vomiting
GU: ↓libido, albuminuria
Hemat: leukopenia
MS: arthralgia, arthritis, neck pain
Neuro: depression, dizziness, drowsiness, dyskinesia (may ↑ levodopa-induced dyskinesia), hallucinations, impulse control disorders (gambling, sexual), malaise, paresthesia, sleep driving, vertigo
Resp: asthma
Drug-drug:
Drug-Natural Products:
Hepatic Impairment
Lab Test Considerations:
Toxicity and Overdose: